Angie You, Ph.D.
Angie You is currently the CEO of Architect Therapeutics. She currently serves on the board of Oric Pharmaceuticals, Attovia Therapeutics and Candid Therapeutics. Angie was most recently CEO of Amunix Pharmaceuticals, which was acquired in 2021 by Sanofi. She served as the CBO at Sierra Oncology (acquired by GSK 2021) and Aragon (acquired by Janssen 2014).
​
Dr. You is a scientist by training with a PhD in Biochemistry from Harvard University. She is a co-founder of the Biotech CEO Sisterhood, a community of female biotech CEOs around the world with the mission of advocating, mentoring and helping elevate female leaders in the industry. She is also a co-founder of a new non-profit focused on elevating AAPI representation at the senior levels in biotech and pharma.
About the Sisterhood
The Biotech CEO Sisterhood is a vibrant community dedicated to championing the success of women leaders in the biopharma industry. Rooted in a culture of mutual support and authenticity, the Sisterhood aims to inspire and uplift women while driving meaningful conversations and impact across the industry. As part of our commitment to nurturing the current and future generations of biotech leaders, the Sisterhood hosts summits, local events, and educational sessions. These programs encourage dialogue about the challenges facing women in biotech, share best practices, and enhance leadership effectiveness. Since its inception in 2022, the Biotech CEO Sisterhood has grown to 300+ members. To follow our progress and learn more, please follow us on LinkedIn.
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
​
​Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.